EQL Pharma AB (publ) (STO:EQL)

Sweden · Delayed Price · Currency is SEK

51.40

-1.10 (-2.10%)

At close: Mar 24, 2026

Revenue by Segment

Financials in millions SEK. Fiscal year is April - March.

Millions SEK. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	Mar '20 Mar 31, 2020	Mar '19 Mar 31, 2019	Mar '18 Mar 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Generics for Prescription Pharmacy Sales and Hospital Sales	373.52M	264.17M	259.91M	409.75M	179.14M
Generics for Prescription Pharmacy Sales and Hospital Sales Growth	41.39%	1.64%	-36.57%	128.73%	148.70%
Total	373.52M	264.17M	259.91M	409.75M	179.14M
Total Growth	41.39%	1.64%	-36.57%	128.73%	148.70%

Revenue by Geography

Financials in millions SEK. Fiscal year is April - March.

Millions SEK. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	Mar '20 Mar 31, 2020	Mar '19 Mar 31, 2019	Mar '18 Mar 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Sweden	164.83M	145.28M	162.77M	365.22M	179.14M
Sweden Growth	13.46%	-10.74%	-55.43%	103.87%	-
Other Europe	55.74M	28.24M	9.72M	-	-
Other Europe Growth	97.37%	190.46%	-	-	-
Outside Europe	553.00K	-	-	-	-
Denmark	106.48M	57.21M	68.90M	-	-
Denmark Growth	86.13%	-16.97%	-	-	-
Norway	32.16M	26.55M	15.83M	-	-
Norway Growth	21.13%	67.67%	-	-	-
Finland	13.75M	6.89M	2.69M	-	-
Finland Growth	99.70%	156.08%	-	-	-
Scandinavia	-	-	-	44.54M	-
Total	373.52M	264.17M	259.91M	409.75M	179.14M
Total Growth	41.39%	1.64%	-36.57%	128.73%	-

Source: S&P Global Market Intelligence.